natgillin/translations-raw huggingface dataset:
A method of controlling undesirable vegetation comprising applying to vegetation or an area adjacent the vegetation or applying to soil or water to control the emergence or growth of vegetation a herbicidally effective amount of a compound of claim 6 . A method of controlling undesirable vegetation comprising applying to vegetation or an area adjacent the vegetation or applying to soil or water to control the emergence or growth of vegetation a herbicidally effective amount of a compound of claim 8 . 
Postupak kontrole nepoželjnog raslinja, naznačen time što se sastoji u (a) stavljanju u kontakt nepoželjnog raslinja ili površine neposredno uz raslinje ili (b) predvegetacijskom stavljanju u kontakt tla ili vode s herbicidno djelotvornom količinom najmanje jednog spoja u skladu s bilo kojim od patentnih zahtjeva 1-4 ili herbicidnim pripravkom u skladu s bilo kojim od patentnih zahtjeva 5-8.
ii) weight median particle size d50 of 0.5 to 2.0 um, iii) weight particle size d25 of 0.1 to 1.0 um, as measured according to a sedimentation method, and iv) a BET specific surface area of from 4.0 to 12.0 m2/g, measured by nitrogen gas adsorption using a BET isotherm (ISO 9277:2010), and 
volumnu raspodjelu čestica d75 od 0.7 do 3.0 µm, ii) medijan volume raspodjele čestice d50 od 0.5 do 2.0 µm, iii) volumnu raspodjelu čestica d25 od 0.1 do 1.0 µm, kao što je izmjereno prema postupku sedimentacije, i iv) specifičnu dodirnu površinu prema BET-u od 4.0 do 12.0 m2/g, mjereno adsorpcijom plinovitog dušika upotrebom BET izoterme (ISO 9277:2010),
Thus, it is extremely difficult a priori to state which proteins will and which will not exhibit an affinity for immobilized metal ions. 
Tako, vrlo je teško a priori reći koji proteini će pokazivati a koji neće afinitet za imobilizirane metalne ione.
combining the cellulose fibres and the at least one filler and/or pigment; 
(c) kombiniranja celuloznih vlakana s najmanje jednim punilom i/ili pigmentom;
Zoledronic acid for use according to any preceding claim, wherein the mammal is a human being that receives a total weekly dose of zoledronic acid that is 10 mg to 300 mg. 
6. - Zoledronska kiselina, namijenjena upotrebi u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačena time što je sisavac ljudsko biće koje prima ukupnu tjednu dozu zoledronske kiseline koja je 10 mg do 300 mg.
A composition according to any one of claims 3 to 7, for use in treating or preventing pain, acute inflammation, chronic inflammation, arthritis, inflamed joints, bursitis, osteoarthritis, rheumatoid arthritis, juvenile rheumatoid arthritis, septic arthritis, fibromyalgia, systemic lupus erythematosus, phlebitis, tendinitis, rash, psoriasis, acne, eczema, facial seborrheic eczema, eczema of the hands, face or neck, foreskin infections, athlete's foot, fistulae infections, infected topical ulcers, navel infections in newborns, wrinkles, scars, kelloids, boils, warts and allergic itch, hemorrhoids, a fungal infection and an immunological disorder including an autoimmune disease. 
liječenju ili prevenciji boli, akutne upale, kronične upale, artritisa, upaljenih zglobova, burzitisa, osteoartritisa, reumatoidnog artritisa, juvenilnog reumatoidnog artritisa, artritisa uzrokovanog sepsom, fibromijalgije, sistemskog eritemskog lupusa, flebitisa, tendinitisa, osipa, psorijaze, akni, ekcema, seboroičnog ekcema na licu, ekcema ruku, lica ili vrata, infekcija prepucija, atletskog stopala, infekcije fistula, inficiranih lokalnih ulcera, infekcije pupka kod novorođenčadi, bora, ožiljaka, keloida, potkožnih čireva, bradavica i alergijskog svraba, hemoroida, gljivične infekcije i imunološkog poremećaja uključujući autoimuni poremećaj;
The compositions of the invention may be obtained by conventional procedures using conventional pharmaceutical excipients, well known in the art. 
Smjese iz ovog izuma mogu se pripraviti konvencionalnim postupcima koristeći u struci dobro poznate farmaceutske ekscipijente.
The graph below shows a representative figure from three independent assays. 
Diagram dar niže prikazuje reprezentativnu sliku iz tri neovisna ispitivanja.
• Ar1 is 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-pyrimidinyl, 4-pyrimidinyl, 5-pyrimidinyl, each unsubstituted or substituted at a carbon ring member with one or two Ra moieties; 
Ar1 je 2-piridil, 3-piridil, 4-piridil, 2-pirimidinil, 4-pirimidinil, 5-pirimidinil, svaki nesupstituiran ili supstituiran na članu ugljik prstena sa jednom ili dvije Ra funkcionalne grupe;
The organic-inorganic composite of para. 21, wherein the degree of substitution is selected in a range from 1.5 to 2.5 weight percent hydroxypropyl. 
Zidna gips ploča prema zahtjevu 9, naznačena time, da je stupanj supstitucije odabran iz raspona od 1,5 do 2,5 masenih postotaka hidroksipropila.
The averaged value must be 127, namely half of the full scale, with a deviation of three bits more or less to account for tolerances. 
Prosječna vrijednost mora biti 127, nominalno polovina cijelog iznosa, s tolerancijom od otprilike tri bita.
The present invention relates to a pharmaceutical composition, comprising 3a-hydroxy-3B-methoxymethyl-21-(1'-imidazolyl)-5a-pregnan-20-one or a pharmaceutically-acceptable salt or solvate thereof, and one or more pharmaceutically-acceptable excipients, wherein the composition provides steady state plasma levels of 3a-hydroxy-3B-methoxymethyl-21-(1'-imidazolyl)-5a-pregnan-20-one in a range of from 5 ng/mL to 500 ng/mL for a duration of from 6 h to 24 h following administration. 
Farmaceutski sastav, naznačen time da sadrži 3a-hidroksi-3?-metoksimetil-21-(1'-imidazolil)-5a-pregnan-20-on ili njegovu farmaceutski prihvatljivu sol ili solvat i jedan ili više farmaceutski prihvatljivih ekscipijenata za upotrebu u liječenju opsesivno- kompulzivnog poremećaja, posttraumatskog stresnog poremećaja ili socijalnog anksioznog poremećaja u ljudskom subjektu, pri čemu sastav daje stacionarno stanje razina u plazmi 3a-hidroksi-3?-metoksimetil-21-(1'-imidazolil)-5a-pregnan-20-ona u rasponu od 5 ng/ml do 500 ng/ml u trajanju od 6 sati do 24 sata nakon davanja.
F, G, H, K and L are independently selected from the group consisting of hydrogen, halogen, C1-4 alkyl, halosubstituted C1-4 alkyl, hydroxysubstituted C1-4 alkyl, and C1-4 alkoxy; 
G F, G, H, Ki L se neovisno bira iz skupine koju čine vodik, halogen, C1-4 alkil, halogenom supstituirani C1-4 alkil, hidroksi supstituirani C1-4 alkil i C1-4 alkoksi;
The reaction was stopped by the addition of 150 mL of a 1N HCl solution containing 10 mg/ml ammonium molybdate and 0.38 mg/ml malachite green. 
Reakcija se zaustavlja dodavanjem 150 mL IN HCI otopine koja sadržava 10 mg/ml amonijevog molibdata i 0,38 mg/ml malahit zelenog.
As illustrated in Figure 7 (Scheme 5) the 2'-hydroxyl may be protected and a functional group attached at the C-7 position, as shown for example in Figures 23 through 25. 
Kao što je prikazano na slici 7 (shema 5), 2'-hidroksil može biti zaštićen i funkcionalna skupina vezana na C-7 položaju, kao što je prikazano, na primjer, na slikama 23 do 25.
The use of an amount of an extract or latex isolated from Croton spp. or Calophyllum spp. effective to treat c-IBS for the manufacture of a medicament for the treatment of constipation-predominant irritable bowel syndrome (c-IBS). 
HR P20130203 T1 PATENTNI ZAHTJEVI 1. Količina krofelemera koja je učinkovita za liječenje c-IBS naznačena time da je za uporabu kod liječenja sindroma iritabilnog crijeva zbog prevladavajućeg zatvora (c-IBS).
In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. 
Dodatno, sterilna fiksirana ulja su uobičajeno korištena kao medij za otapanje ili suspenziranje.
The method of claim 1 or claim 2, wherein the number of oil droplets having a size of >1.2 µm in the first emulsion is 5 x 1011 /ml or less. 
Postupak prema zahtjevu 1 ili zahtjevu 2, naznačen time da broj uljnih kapljica koje imaju veličinu od >1.2 um u prvoj emulziji je 5 x 10"! /ml ili manje.
The polyester polymer of claim 1, wherein said phenolic stabilizer is from 200 to 300 ppm. 
Poliesterski polimer u skladu s patentnim zahtjevom 1, naznačen time što je navedeni fenolni stabilizator u količini od 200 do 300 ppm.
Pharmaceutical composition according to any one of claims 1, 4 or 5, wherein the inflammatory pulmonary disease is selected from the group consisting of asthma, COPD, sclerosis, alveolitis, sarcoidosis, idiopathic pulmonary fibrosis and pulmonary hypertension. 
Farmaceutski sastav prema bilo kojem od zahtjeva 1, 4, 5, 6, 7 ili 8, naznačen time, da je upalna plućna bolest odabrana iz skupine koju čine: astma, COPD, skleroza, alveolitis, sarkoidoza, idiopatska plućna fibroza i plućna hipertenzija.
exposing the bound Micafungin to an aqueous solution of a dissolved pharmaceutically acceptable salt; 
izlaganje vezanog Micafungina vodenoj otopini otopljene farmaceutski prihvatljive soli;
selected from the group consisting of greater than or equal to about 30 seconds, 1 minute, 2 minutes, 3 minutes, 4 minutes, 5 minutes, 10 minutes, 30 minutes, and 60 minutes; or such that the ratio of the measured level of aptamer affinity complex to the measured level of the non-specific complex is increased. 
Ne-kovalentni kompleks prema zahtjevu 6, naznačen time, da je brzina razdruživanja (ti/2) aptamera iz ciljane molekule, veća ili jednaka vremenu od 30 minuta.
The top coating may be applied by any known technique like roller coating, reverse and inreverse, spraying, curtain, screen etc. 
Gornji se sloj može nanijeti bilo kojim poznatim postupkom, poput nanošenja valjcima, u suprotnim smjerovima, prskanjem, kao zastor, raster itd.
Method according to claim 3, characterized in that said size reducing means (3) consists of at least one series of parallel or intersecting sheets or wires that form at least one size reducing net. 
Metoda u skladu sa patentnim zahtjevom 4, naznačena time da se sredstva (3) za smanjivanje veličine sastoje od najmanje jedne serije paralelnih ili presjecajućih ploča ili žica koje formiraju najmanje jednu mrežu za smanjivanje veličine.
The quality of the pelletization technology can be characterized by the product fraction, that is by the ratio of the mass of the pellets having the desired particle size to the total mass of the pellets. 
Kakvoća tehnologije granuliranja može će karakterizirati frakcijom produkta, dakle odnosom mase granula koje imaju željenu veličinu čestica prema ukupnoj masi granula.
ii) then reacting the obtained N-(2,2-dimethoxyethyl)-2-(3,4-dimethoxyphenyl)-acetamide of formula (V) with an anhydrous acid to furnish the compound of formula (II), wherein the anhydrous acid is methanesulfonic acid or hydrogen bromide in acetic acid. 
ii) zatim reakcijom dobivenog N-(2,2-dimetoksietil)-2-(3,4-dimetoksifenil)-acetamida formule (V) s bezvodnom kiselinom kako bi se dobio spoj formule (II), pri čemu je bezvodna kiselina metansulfonska kiselina ili bromovodik u octenoj kiselini.
In one embodiment B is substituted by methyl. 
B supstituiran, može biti supstituiran s metilom.
Method as claimed in the preceding claims characterized by wholly coating the bottom of the said formwork with a layer of non woven fabric or equivalent sealing means. 
Postupak sukladno zahtjevima 10 i 11 naznačen daljnjim korakom potpunog prekrivanja okvira slojem netkanog materijala ili ekvivalentnog sredstva za zatvaranje.
The antibody for use according to any one of claims 1-5, wherein there is a post-administration reduction in absolute basophil count of at least about 5, at least about 10, at least about 15, at least about 20, at least about 25, at least about 30, at least about 35, at least about 40, at least about 45, at least about 50, at least about 55, at least about 60, at least about 65, or at least about 70 basophils/mm3. 
Protutijelo za uporabu prema bilo kojem od zahtjeva 1-4, naznačeno time da postoji smanjenje apsolutnog broja bazofila nakon davanja od barem 5, barem 10, barem 15, barem 20, barem 25, pri barem 30, barem 35, barem 40, najmanje 45, barem 50, barem 55, barem 60, barem 65 ili barem 70 bazofila/mm".
The ratios of components A) and C) in the mixture in general range from 1:0.002 to 1:800, preferably from 1:0.003 to 1:160, particularly preferably from 1:0.02 to 1:160. 
Proporcije komponenti A) i €) u smjesi su generalno u opsegu od 1:0.002 do 1:800, poželjno od 1:0.003 do 1:160, posebno poželjno od 1:0.02 do 1:160.
reacting said compound of formula (VI) with 1,2-dibromoethane to obtain a compound of formula (VII): 
(1v) reakcija spoja formule (VI) sa 1,2-dibrometanom čime nastaje spoj formule (VII), te
The composition of claim 1, wherein the solid form comprises a particle and/or a powder. 
Pripravak prema zahtjevu 1, naznačen time da kruti oblik sadrži čestice i/ili prašak.
In this way the process for regulating the size of knitted articles can also enable maintaining the balance of the previously-obtained fabric. 
Postupak reguliranja veličine pletenih artikala koji se proizvode na kružnim strojevima za pletenje pletenih odjevnih predmeta ili čarapa, koji sadrže sljedeće korake:
In one embodiment of the invention, the rVWF comprises the amino acid sequence set out in SEQ ID NO: 3; wherein the buffering agent is citrate and the pH is about 7.3; and wherein the amino acid is glycine at a concentration of about 15 mM. 
Formulacija prema zahtjevu 1, naznačena time da rVWF sadrži amino kiselinsku sekvencu prikazanu kao SEQ ID NO:3; gdje je pufer otopina citrata i pH je oko 7.3; i gdje je amino kiselina glicin u koncentraciji od oko 15 mM u otopini.
Inorganic or organic substances, or solid or liquid substances may be used as pharmaceutical additives. 
Kao farmaceutske aditive može se upotrijebiti anorganske ili organske tvari, ili čvrste ili tekuće tvari.
Operation of mixing member 1 will be clear from the foregoing description and attached drawings, with no further explanation required, except to state that elastic members 9 are able to keep the wedge-shaped transverse edge 8a of corresponding scrapers 8 resting on the cylindrical inner surface of bowl 2, and scrapers 8 are fixed to longitudinal blades 4 so that the mechanical resistance produced by the ice-cream accumulating on wedge-shaped transverse edge 8a and on the body of scraper 8 is added to the action of elastic members 9 to proportionally increase the radial force with which the wedge-shaped transverse edge 8a of scraper 8 is pushed against the wall of bowl 2. 
Rad članka za miješanje 1 će biti jasan iz daljnjih opisa i priloženih crteža bez potrebe za daljnjim objašnjenjima, osim za stanje da su elastični članci 9 sposobni da drže klinasto oblikovane poprečne bridove 84 odgovarajućih strugača 8 naslonjenim na cilindričnu unutarnju plohu zdjele 2, a strugači 8 su fiksirani na uzdužne lopatice 4 tako, da se mehanički otpor, proizveden sladoledom koji se akumulira na klinasto oblikovanom poprečnom bridu &$a i na tijelu strugača 8, dodaje djelovanju elastičnih članaka 9 da se proporcinalno poveća radijalna sila s kojom se klinasto oblikovani poprečni brid 84 strugača 8 potiskuje prema stijenci zdjele 2.
The residue was basified with solid sodium carbonate and extracted with ethyl acetate (200 ml and 100 ml). 
Ostatak se zaalkali s čvrstim natrij-karbonatom i ekstrahira s etilacetatom (200 ml i 100 ml).
An aqueous suspension of an enkephalinase inhibitor suitable for oral administration, wherein said suspension has a pH comprised between 3.5 and 5. 
Vodena suspenzija inhibitora enkefalinaze pogodna za oralno davanje, naznačena time što navedena suspenzija ima pH između 3,5 i 5, pri čemu navedeni inhibitor enkefalinaze predstavlja racekadotril.
a, b and c respectively denote, independently from each other, a single bond or a double bond, with the proviso that at least one of a, b and c represents a double bond, and with the proviso that if a is single bond and b is double bond, R2 is not H; 
Formula 1 gdje a, bic, međusobno neovisno, odgovarajuće označuju jednostruku vezu ili dvostruku vezu, uz uvjet da najmanje jedan od a, b i c predstavlja dvostruku vezu, te uz uvjet da ako je a jednostruka veza, a b je dvostruka veza, R> nije H;
The pharmacological profile of trans-5-chloro-2-methyl-2,3,3a,12b-tetrahydro-1H-dibenz[2,3:6,7]oxepino[4,5-c]pyrrole, its kinetics and metabolism, as well as the first safety and efficacy studies in human volunteers and in schizophrenic patients were reviewed by De Boer et al. 
Farmakološki profil trans-5-kloro-2-metil-2,3,3a,12b-tetrahidro-IH-dibenz[2,3:6,7]oksepino[4,5-c]pirola, njegova kinetika i metabolizam, kao i prva ispitivanja sigurnosti i učinkovitosti na volonterima i pacijentima sa shizofrenijom pregledno su opisani od strane De Boer i sur.
an inverse transformer that performs inverse-quantization and inverse-transformation on the quantized transformation coefficients of the at least one transformation unit to obtain residuals; and 
Uređaj za kodiranje slike, te uređaj sadrži: memoriju koja pohranjuje tok bitova; i najmanje jedan procesor konfiguriran za:
According to a further embodiment of the method, the pressure of the inner compartment can be controlled by dry gas injection means and, or gas extraction means. 
Postupak prema zahtjevu 26, naznačen time, da se tlakom unutrašnjeg odjeljka (14) upravlja pomoću naprave za injektiranje suhog plina (18) i, ili pomoću naprave za izvlačenje plina (23).
A process for preparing a compound of formula I, wherein: 
PATENTNI ZAHTJEVI 5 Postupak dobivanja spoja formule I
X is selected from the group consisting of 
A je odabrana iz skupine koju čine
This application is a division U.S. Ser. 
US (73) Nositelj patenta:
A method for assessing renal toxicity in an individual following administration of compound suspected of causing renal toxicity, wherein the renal toxicity is identified by measurement of a set of biomarkers in a urine sample from the individual and comparison of the measured biomarker amount with the corresponding amount in a healthy individual, wherein the biomarkers are selected from the group consisting of the biomarkers listed in TABLE 1 and include B-2-microglobulin protein, and wherein the renal toxicity is glomerular alterations or damage. 
Postupak za procjenu bubrežne toksičnosti kod pojedinca nakon davanja spoja za koji se sumnja da izaziva bubrežnu toksičnost, naznačen time da se bubrežna toksičnost utvrđuje mjerenjem skupa biomarkera u uzorku urina pojedinca, te se provodi usporedba iznosa izmjerenih biomarkera s odgovarajućim iznosom kod zdravog pojedinca, pri čemu su biomarkeri su odabrani iz skupine koja se sastoji od biomarkera navedenih u tablici 1, a uključuju 2-mikroglobulinski protein, te gdje renalna toksičnost su glomerulske promjene ili oštećenja.
The method according to claim 11, wherein the HIV is multiresistant HIV. 
Spoj za uporabu prema zahtjevu 19, gdje je HIV multirezistentni HIV.
This allows the operator to run a clean out by manual selection. 
To omogućuje operateru da izabere ručno čišćenje.
The method of claim 1, wherein steps b) to d) are also carried out on the reverse side of the base layer to manufacture a print medium being coated on the first side and the reverse side. The method of claim 1, wherein the absorptive layer has an absorption rate from 1×10−5 ms−0.5 to 1×10−3 ms−0.5 and/or a volume uptake from 30 to 95% by volume relative to the total volume of the absorptive layer. 
Tiskovna podloga prema bilo kojem od prethodnih zahtjeva, naznačena time da apsorpcijski sloj sadrži pigment, koji, kada je u kompaktnom obliku, ima stupanj upijanja od 1×10-5 ms-0.5 do 1×10-3 ms-0.5 i/ili unos volumena od 35 do 95 % volumena u odnosu na ukupni volumen pigmenta.
A recognition memory task allows the comparison between presented stimuli and previously stored information. 
Obrazac memoriranja prepoznavanja dozvoljava usporedbu između prisutno stimulacije i ranije pohranjenih podataka.
reacting an acid addition salt of formula (I) to form a free base compound of formula (I); or 
reakciju dodatne kiselinske soli formule (I) za tvorbu spoja formule (I) sa slobodnom bazom; ili
In one embodiment, the salt of formula VII is rosuvastatin 1-[(4-chlorophenyl)-phenyl-methyl]piperazinium salt which exhibits a powder x-ray diffraction pattern measured using CuKa-radiation having characteristic peak locations of 10.0, 16.7, 17.9 and 20.2 ± 0.2 degrees 2θ, particularly 10.0, 11.6, 16.7, 17.9, 20.2, 22.5 and 23.7 ± 0.2 degrees 2θ, more preferably exhibits a powder x-ray diffraction pattern substantially as shown in Fig. 1 . 
Sol prema zahtjevu 5, naznačena time, da je to rosuvastatin-1-[(4-klorofenil)-fenil-metillpiperazin-sol koja prikazuje uzorak difrakcije praha X-zraka mjeren uporabom CuKa-radijacije, s mjestima karakterističnih vršnih vrijednosti na 10,0, 16,7, 17,9 1 20,2 + 0,2 stupnjeva 20, poželjno na 10,0, 11,6, 16,7, 17,9, 20,2, 22,5 i 23,7 +0,2 stupnjeva 20, i još bolje pokazuje uzorak difrakcije praha X-zraka uglavnom kako je prikazano na slici 1.
A method according to any of the preceding claims, wherein the fiber cement product is a fiber cement plate having at least one profiled surface comprising at least one groove. 
Postupak prema bilo kojem od prethodnih patentnih zahtjeva, naznačen time što vlaknasti cementni proizvod je ploča od vlaknastog cementa koja ima najmanje jednu profiliranu površinu koja sadrži najmanje jedan žlijeb.
The organic layer was dried, filtered, and concentrated to give a foam of Formula 38. 
Organski sloj je bio osušen, filtriran i koncentriran da bi se dobila pjena formule 38.
A composition according to claim 1, which comprises as component (A) the compound 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid (9-dichloromethylidene-benzonorbornene-5-yl)amide and as component (B) mandipropamid. 
Pripravak prema zahtjevu 1, naznačen time da kao komponentu (A) sadrži spoj 3-difluorometil-1-metil-1 Hpirazol-4-karboksilna kiselina (9-diklorometiliden-benzonorbornen-5-iljamid, te kao komponentu (B) spoj koji je izabran između slijedećeg: difenokonazola, propikonazola, kiprokonazola i epoksikonazola.
X4, X5, X6 and X7 are each selected from the group consisting of N, 
X*, X", Xi X/ su svaki izabran iz grupe koja se sastoji od
The method of claim 16, wherein said stabilizing agent is trehalose at a concentration of about 2% to about 4% w/v. 
navedeno sredstvo za dopunjavanje je 4 % w/v manitol; i navedeni stabilizator je 2% w/v saharoza;
contacting the solution or suspension of tin (II) oxide with the solution or suspension of mesoporphyrin IX dihydrochloride or salt thereof by dropwise addition of the solution or suspension of mesoporphyrin IX dihydrochloride or salt thereof to form the tin (IV) mesoporphyrin compound or salt thereof; and 
miješanja otopine ili suspenzije kositrenog(II) oksida s otopinom ili suspenzijom Mezoporfirin IX-dihidroklorida, ili njegove soli, gdje se otopinu ili suspenziju Mezoporfirin IX-dihidroklorida ukapava, kako bi se dobilo kositar(IV)-mezoporfirinski spoj, ili njegovu sol; i